This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

05/19/15 - 04:42 PM EDT

Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.


An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

05/19/15 - 12:48 PM EDT

There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.


Investors Get Teary Over Eleven Biotherapeutics' Dry-Eye Drug Failure

05/18/15 - 08:06 AM EDT

Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.


Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase

05/05/15 - 02:43 PM EDT

The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.


NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis

05/05/15 - 10:40 AM EDT

The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.


Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

04/29/15 - 09:01 AM EDT

Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.


Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

04/21/15 - 07:48 AM EDT

Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.


Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

04/20/15 - 10:22 AM EDT

Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.


If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

04/16/15 - 09:07 AM EDT

In which Musk learns how to put a happy spin on failure from biotech CEOs.


Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

04/15/15 - 11:35 AM EDT

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.


Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -


DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs